MAP2K7 and metastatic melanoma: Multiple combinations of BRAF/MEK inhibitors have recently found to be highly efficacious for the use in metastatic melanoma, metastatic non‐small cell lung cancer, and metastatic colon cancer,3, 4, 5, 6, 7, 8, 9 which include vemurafenib (BRAF)/cobimetinib (MEK), dabrafenib (BRAF)/trametinib (MEK), and encorafenib (BRAF)/binimetinib (MEK).